Drug Development, Insiders, Regulatory

With its rep on the line, Celgene’s newly-filed safety study spurs fresh worries over fate of ozanimod

After blundering its way into an ugly setback at the FDA with its highly anticipated multiple sclerosis drug ozanimod, Celgene is triggering fresh questions about the future of this frequently touted blockbuster-to-be with a slate of newly filed clinical trials aimed at further exploring possible safety issues. And that has at least one prominent analyst wondering if he will need to eventually recalculate the timing — and chances of success — of the marketing pitch.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 35,600+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->